Drug · PCSK9 / LDL-C · PCSK9 / LDL-C · Verified drug
Enlicitide (Lipfendra) structure · mechanism
First FDA-approved once-daily oral PCSK9 inhibitor (macrocyclic peptide); adjunct to diet/exercise for hypercholesterolemia including HeFH.
Enlicitide (Lipfendra) 2D structure
- Role
- Drug
- Mechanism class
- PCSK9 / LDL-C
- Parent scaffold
- PCSK9-binding macrocyclic peptide pharmacophore
- Indication
- Oral macrocyclic PCSK9i · Investigational
- Structure source
- Catalog seed
- FDA / EMA
- Investigational
- ClinicalTrials.gov
- enlicitide MK-0616
- Regulatory status
- P3 · Investigational · ClinicalTrials.gov · ClinicalTrials.gov
Hand-written analysis
Mechanism
엔리시타이드(MK-0616)는 경구 PCSK9 매크로사이클입니다. 항체·siRNA가 아닌 소분자/펩타이드 유사 경구로 PCSK9–LDLR 축을 겨냥합니다.
Medicinal chemistry
경구 매크로사이클 케모타입입니다. 에볼로쿠맙·인클리시란과 개입 층이 다릅니다.
Indication · context
LDL-C 경구 PCSK9 임상 자산입니다. /briefs/pcsk9-oral-sirna의 세 번째 축입니다.
SMILES
CC(C)C[C@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)CCCCCCCCC(=O)O)CCC(=O)N1Tags
Related compounds
External IDs · BioMoa
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.